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ABSTRACT  
 
Objective: To identify shared polygenic risk and causal associations in amyotrophic 
lateral sclerosis (ALS).  
Methods: Linkage disequilibrium score regression and Mendelian randomization were 
applied in a large-scale, data-driven manner to explore genetic correlations and causal 
relationships between > 700 phenotypic traits and ALS. Exposures consisted of publicly 
available genome-wide association studies (GWASes) summary statistics from MR Base 
and LD-hub. The outcome data came from the recently published ALS GWAS involving 
20,806 cases and 59,804 controls. Multivariate analyses, genetic risk profiling and 
Bayesian colocalization analyses were also performed. 
Results: We have shown via linkage disequilibrium score regression that ALS shares 
polygenic risk genetic factors with a number of traits and conditions, including positive 
correlations with smoking status and moderate levels of physical activity, and negative 
correlations with higher cognitive performance, higher educational attainment, and light 
levels of physical activity. Using Mendelian randomization, we found evidence that 
hyperlipidemia is a causal risk factor for ALS and localized putative functional signals 
within loci of interest.  
Interpretation: Here we have developed a public resource (https://lng-
nia.shinyapps.io/mrshiny) which we hope will become a valuable tool for the ALS 
community, and that will be expanded and updated as new data become available. Shared 
polygenic risk exists between ALS and educational attainment, physical activity, smoking 
and tenseness/restlessness. We also found evidence that elevated LDL cholesterol is a 
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causal risk factor for ALS. Future randomized controlled trials should be considered as a 
proof of causality. 
 
 
INTRODUCTION 
 
Amyotrophic lateral sclerosis (ALS, OMIM #105400) is a progressive, fatal 
neurodegenerative disease. Symptom onset of ALS peaks in the mid-sixties, and most patients 
succumb to the disease within two to five years of becoming symptomatic 1. The prevalence 
of ALS is projected to nearly double by 2040, primarily due to aging of the global population 
2. 
Despite considerable advances made in understanding the genetic architecture underlying 
ALS 3,4, the contribution of lifestyle factors and of disease-related conditions predisposing 
individuals to the disorder have been more difficult to elucidate. Epidemiological studies 
have attempted to identify risk factors and comorbidities associated with ALS, although the 
inability of such observational research to fully mitigate confounding effects or to exclude 
reverse causality has made it challenging to find replicable causes of the disease 5. 
Genome-wide association studies (GWAS) have revolutionized human genetics and have led 
to the discovery of thousands of risk variants involved in disease etiology 6. From the 
perspective of ALS research, summary statistics from hundreds of these studies have been 
published online in an effort to facilitate the application of current generation genomic 
techniques, such as linkage disequilibrium (LD) score regression testing and Mendelian 
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randomization. Both methodologies are powerful tools to assess causality and investigate the 
extent to which genetic etiologies are shared across different diseases.  
LD score regression and Mendelian randomization test distinct aspects of the genetic 
architecture underlying a disease. More specifically, LD score regression investigates whether 
polygenic risk contributing to a phenotype of interest might also contribute to the risk of ALS. 
This approach relies on the identification of shared genome-wide heritability to pinpoint 
overlapping polygenic genetic variation between traits (pleiotropic relationship) 7. On the 
other hand, Mendelian randomization uses genetic data to assess whether an exposure exerts a 
causal effect on a particular outcome 8. In contrast to LD score regression, Mendelian 
randomization usually focuses on genome-wide significant SNPs for the exposure of interest 
(causal relationship) 8. As this analytical technique relies solely on genetic elements that 
remain constant over the lifespan of an individual, and that are randomized during 
gametogenesis, it effectively excludes reverse causality and reduces confounding to allow 
more reliable identification of a causal association between exposure and outcome.   
Recent ALS related Mendelian randomization studies have focused on a hypothesis driven by 
only a single trait 9-11. Here, we implemented LD score regression and Mendelian 
randomization in a large-scale audit relevant to ALS. In brief, our goal was to survey curated 
libraries of GWAS results using LD score regression and Mendelian randomization. The 
former is more liberal in identifying shared variation that suggests a significant degree of 
shared genetic risk, whereas the latter is more conservative and attempts to pinpoint causal 
associations via established loci. We also created an online resource (https://lng-
nia.shinyapps.io/mrshiny) that can be used by the ALS community to inform pleiotropy or 
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causality when undertaking observational studies or pursuing disease-modifying interventions. 
 
METHODS 
Outcome data 
Summary statistics from our recently published GWAS of ALS involving 20,806 cases and 
59,804 controls of European ancestry were used as the outcome for both LD score regression and 
Mendelian randomization analyses. This study included 10,031,630 genotyped and imputed 
variants. Sample recruitment and genotyping quality control procedures are described  
elsewhere 4. 
 
Linkage disequilibrium score regression 
LD patterns across the genome enable the calculation of genetic correlations between traits. This 
is because the observed association for a SNP is a product of both its own contribution toward a 
phenotype and the association of the SNPs that are in LD with it. SNPs in regions of high LD tag 
a greater proportion of the genome and will show stronger associations than SNPs in regions of 
low LD. Using the known LD structure of a reference SNP panel, the heritability of a single 
phenotype or the genetic correlation of two phenotypes can be computed using LD score 
regression 7,12.  
To study shared genetic risk via LD score regression, we used LD Hub, a centralized database of 
summary-level GWAS results across multiple diseases/traits gathered from publicly available 
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resources 13. LD score regression was implemented by regression of the chi-squared statistics for 
the genetic associations with the trait against the LD scores for genetic variants across the whole 
genome. Unlike Mendelian randomization, LD score regression does not assess casualty, but 
rather only assesses multi-directional correlations and can distinguish between population 
stratification and polygenicity in GWAS studies. Default settings were used in our analyses.  
 
Mendelian randomization 
Mendelian randomization is a proxy-based approach for exploring whether an exposure is causally 
associated with an outcome. This is done by: identifying the single nucleotide polymorphisms 
(SNPs) associated with a particular exposure (for example, SNPs identified in a genome-wide 
association study (GWAS) as being associated with colon cancer); extracting data for those SNPs 
from the outcome (in this case, a large-scale GWAS of ALS 4); harmonizing the exposure and 
outcome summary data; and, applying Mendelian randomization methods to test for a causal 
relationship between the exposure and the outcome rooted in genetic associations. 
 
Similar to LD-Hub, MR Base database is a curated database containing summary results from 
1,094 GWASes involving 889 traits 14 . These traits encompass a wide range of physiological 
characteristics and disease phenotypes. Each trait was tested separately as an exposure to 
determine if it alters risk of developing ALS. The analyses were performed using the R package 
TwoSampleMR (version 3.2.2). The instrumental variables used for each exposure/phenotype 
consisted of the per-allele log-odds ratio (i.e., beta estimate) and standard errors for all 
independent loci (i.e., SNPs) reaching genome-wide significance in the tested GWAS. Of the 
1,094 GWASes with data available in MR Base (accessed 15th August 2018), 635 GWASes 
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(consisting of 345 published GWASes and 290 unpublished GWASes performed on the UK 
Biobank, www.ukbiobank.ac.uk) were included in our analysis based on the following criteria: (i) 
GWAS with at least two associated SNPs with p-values less than 5.0x10-8, considering this p-
value to be the generally accepted genome-wide significant threshold; (ii) SNPs present in both 
the exposure and outcome (ALS) datasets or when not present their linkage-disequilibrium proxies 
(R2 value >= 0.8); and, (iii) independent SNPs (R2 < 0.001 with any other associated SNP within 
10 Mb), considered as the most stringent clumping threshold used when performing Mendelian 
randomization analyses.   
Harmonization was undertaken to rule out strand mismatches and to ensure alignment of SNP 
effect sizes. Within each exposure GWAS, Wald ratios were calculated for each extracted SNP by 
dividing the per-allele log-odds ratio of that variant in the ALS data by the log-odds ratio of the 
same variant in the exposure data. We then applied a two-step approach designed to decrease the 
risk of false positive associations (see Fig 1 for the workflow).  
First, the inverse-variance weighted method was implemented to examine the relationship 
between the exposure and ALS. In this method, the Wald ratio for each SNP is weighted 
according to the inverse variance, and a line, constrained to pass through the origin, is fitted to the 
data. The slope of the line represents the pooled-effect estimate of the Wald ratios 15. Traits were 
brought forward to the next stage of analysis only if the p-value of the pooled-effect estimate was 
less than or equal to 0.05.  Next, two Mendelian randomization sensitivity tests (i.e., MR Egger 
and Weighted Median) were applied to those traits/GWASes passing the first phase of analysis. 
These sensitivity analyses evaluated core assumptions of Mendelian randomization, and traits 
were considered to be consistent with a causal effect when p-values were less than or equal to 
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0.05. Heterogeneity of effects were tested using the Cochran’s Q test, quantified using the I2 
statistic, and displayed in forest plots. Steiger analyses were performed to verify that the proposed 
instruments were directly associated with the outcome 16 or effect estimate directionality.  
We evaluated the possibility that the overall estimate was driven by a single SNP using leave-one-
out analyses for each of the GWASes associated with ALS. We further explored the possibility of 
reverse causality by using SNPs tagging the five independent loci described in the ALS GWAS as 
exposure instrument variables, and the identified GWASes as the outcome. Lasso-based 
multivariate analysis was used to explore how each related exposure of interest (i.e., low-density 
lipoprotein (LDL cholesterol), self-reported cholesterol, and coronary heart disease) 
independently contribute to ALS.  
 
Genetic risk score 
To further test the relationship between LDL cholesterol and ALS, a cumulative genetic risk score 
for LDL cholesterol was calculated in a smaller subset of the samples for which individual 
genotype data were available, including 8,229 ALS cases and 36,329 controls 4. The instrumental 
variables of interest were incorporated and weighted by beta values in the ALS GWAS. Next, a 
logistic regression was performed on this subset of cases and controls, regressing disease against 
quintile membership based on genetic risk score 17. Odds ratios were reported comparing the 
lowest risk quintile (reference group) to the remaining quintiles. Genetic risk scores were also 
calculated for different subtypes of ALS patients (carriers of the pathogenic C9orf72 repeat 
expansion, familial cases, sporadic cases, male cases and female cases). Risk profiling was 
adjusted for sex, age, and twenty principal components to account for population stratification. 
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 Colocalization analysis 
Bayesian colocalization analysis was used as a statistical method to identify putative candidate 
genetic variants involved in LDL cholesterol blood levels that contribute most to the risk of 
developing ALS 18. For these analyses, we considered the 78 SNPs that were significantly 
associated with increased LDL cholesterol and were used as relevant instrumental variables for 
Mendelian randomization analyses. We extracted summary statistics for those variants (as well as 
variants one megabase (Mb) upstream and downstream) from the LDL cholesterol GWAS and 
from the ALS GWAS. Bayesian colocalization was then run for each independent region as 
implemented in the R package coloc (https://CRAN.R-project.org/package=coloc). This analysis 
assessed the probability of each SNP being responsible for the change in ALS risk through 
variation in LDL cholesterol. We derived posterior probabilities (PPH0-4) for each region and 
considered PPH4 greater than 0.95 as strong evidence for colocalization under the assumption of a 
single causative variant per locus. 
 
 
RESULTS 
Large-scale linkage disequilibrium score regression analysis in ALS 
LD score regression was applied to examine the genetic correlation between our recently 
published GWAS meta-analysis of ALS 4 and 736 phenotypes available in LD-hub, a centralized 
database of GWAS results across multiple diseases and traits (http://ldsc.broadinstitute.org/ldhub/, 
Fig 1).  
 
Traits genetically correlated to ALS by linkage disequilibrium score regression 
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Our analyses identified eighteen traits that were genetically correlated to ALS after adjusting for 
multiple testing via false discovery rate (Table 1). Among these, nine traits were related to 
educational attainment and intelligence, indicating that higher levels of education were associated 
with a decreased risk of ALS (smallest adjusted p-value = 1.78x10-4; regression coefficient  = -
0.338; 95% confidence interval (CI) = -0.46, -0.20).  
Traits related to light physical activity including walking for pleasure, walking as a mean of 
transport and light DIY physical activities were associated with decreased risk of developing ALS 
(smallest adjusted p-value = 5.19x10-4; regression coefficient = -0.403; 95% CI = -0.35, -0.14), 
whereas heavier activity levels such as duration of moderate activity and performing a job that 
involves mainly walking or standing were positively associated to ALS (smallest adjusted p-value 
= 3.09x10-2; regression coefficient  = 0.28; 95% CI = -0.36, -0.09). 
Smoking behaviour including Exposure to tobacco and being a light smoker showed genetic 
correlation with ALS (smallest adjusted p-value = 1.66x10-3; regression coefficient  = 0.42; 95% 
CI = 0.23, 0.62). Detailed results for the remaining 718 non-significant traits are shown in Table 
S1 and can be interactively searched at https://lng-nia.shinyapps.io/mrshiny. 
 
Large-scale Mendelian randomization in ALS 
Next, we performed Mendelian randomization to further investigate causal links between 
multiple phenotypic traits (exposures) and ALS (outcome, Fig 1). The exposures of interest 
consisted of 345 GWASes involving a wide range of physiological characteristics and disease 
phenotypes for which data was available in MR Base (http://www.mrbase.org/). The recently 
published GWAS of ALS involving 20,806 cases and 59,804 controls was used as the outcome 
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4. 
There are no previous reports in the literature where multiple phenotypes were tested using 
Mendelian randomization in an unbiased, hypothesis-free manner. This raised concerns about 
false-positive associations and multiple-testing correction. To control for this and to confirm 
the validity of our findings, we replicated in an independent collection of phenotypes (290 
unpublished GWASes performed on the UK Biobank, www.ukbiobank.ac.uk). Here, we only 
report associations that were significant across both the published and unpublished sets of 
GWASes. Detailed results for the 635 GWAS under study are shown in Tables S2-S4 and can 
be visually explored at https://lng-nia.shinyapps.io/mrshiny.  
Traits causally linked to ALS by Mendelian randomization 
We identified the phenotypic traits LDL cholesterol and coronary heart disease in the 
published GWASes, and self-reported high cholesterol in the UK Biobank, as being causally 
linked to ALS risk (see Table 2 and Table S5 for SNPs used to construct the instruments of 
interest. Multivariate analysis showed that the signals arising from the coronary heart disease 
and self-reported high cholesterol were driven by SNPs related to LDL cholesterol, revealing 
that both traits represent closely-related phenotypes (Table 3). 
Leave-one-out analysis indicated that no single SNP accounted for these associations in 
isolation (Table S6). Additional analyses examining directionality, pleiotropy, and reverse 
causality did not indicate any violation of core Mendelian randomization assumptions for these 
traits (Table S7-S8). We used genetic risk profiling to estimate the extent to which risk of 
developing ALS is attributable to LDL cholesterol. We found that individuals with the highest 
burden of genetic risk were 1.075 times more likely to develop ALS (95% CI, 1.001–1.15, p-
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value = 0.003). The increase in ALS risk associated with LDL cholesterol levels was similar 
across different subtypes of ALS (C9orf72 carriers, familial ALS, sporadic ALS, male and 
female-only cases, Table S9). 
 
Identification of functional causal variants 
Bayesian colocalization analysis was performed to putatively identify the functional candidate 
variants that may drive risk of developing ALS through shared pathway effects of LDL 
cholesterol levels. We focused our efforts on the 78 independent regions associated with LDL 
cholesterol in the exposure GWAS. This analysis identified two independent regions with 
greater than 95% probability of containing a shared causal SNP (Table S10). Fine mapping of 
these regions identified two SNPs (rs182826525 within COL4A3BP and rs116226146 
intergenic between PPP1R2P3 and TIMD4) as being causally linked to ALS through an 
increase of LDL cholesterol levels (Fig 2). 
 
DISCUSSION 
We applied cutting-edge analytical techniques to genomic data across a wide range of phenotypic 
traits to identify factors associated with risk of developing ALS. This hypothesis-free, data-driven 
approach provided prima facie evidence supporting the existence of multiple such factors. Using 
genetic data to comprehensively map the risk factor landscape of ALS represents a novel approach 
in neurological disease. We used these results from nearly 25 million individuals (24,538,000 
from published GWAS and ~ 337,159 from UKBB studies) to establish a public resource that can 
be accessed by other researchers to explore risk factors and shared disease mechanisms in ALS. 
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LD score regression analyses found that common genetic variation associated with higher 
cognitive performance is negatively correlated to ALS. At a molecular level, these findings 
indicate that the genetic factors driving mental ability and ALS overlap to some extent. This may 
have been an expected outcome given the well-known relationship between ALS and 
frontotemporal dementia, and our findings are consistent with previous epidemiological reports 
assessing the causal relationship between education and ALS 19. Nevertheless, the large number of 
samples analyzed in our study and its grounding in genetics puts this risk factor on a firmer 
footing within the ALS field. Similar education effects have been observed in Alzheimer’s disease 
20, but understanding how education protects against neurodegeneration or which genetic variants 
are responsible for this shared risk will require additional study. One intriguing possibility is that 
the genetic variants responsible for ALS in middle age or in the elderly are also associated with 
decreased cognitive performance at a younger age. This is plausibly consistent with the 
observation that connectivity and grey matter volumes are altered in asymptomatic carriers of the 
C9orf72 repeat expansion 21-22. 
Epidemiological case-control studies have extensively reported a relationship between exercise 
and risk of developing ALS 23-25, though there are conflicting results as to the level of physical 
activity required to increase risk 19. Our genetic-based data demonstrate that this neuromuscular 
interconnection may be more complex than previously appreciated: light physical activity 
including ‘Walking for pleasure’ or ‘Light DYI activities’ was negatively associated with 
developing ALS, whereas more strenuous activity, such as ‘duration of moderate activity’ was 
paradoxically correlated with ALS. Extrapolating from these observations to neuromuscular 
physiology, relatively low levels of exercise may exert a neuroprotective effect by preventing 
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muscle atrophy that, in turn, supports motor neuron integrity though the neuroadaptive generation 
of neurotrophic factors 26). In contrast, excessive physical activity may be detrimental to motor 
neurons due to excessive free radical production and/or glutamate excitotoxicity that overwhelms 
neuroprotective mechanisms 27,28. Regardless, our data does not provide any insight into the effect 
of exercise on survival once the patient has presented with symptoms. 
There is compelling epidemiological evidence showing that cigarette smoking is a key 
environmental risk factor for ALS 29. Our LD data not only confirms that being a smoker is 
positively correlated to developing ALS, but also shows that this effect is mediated, at least in 
part, through shared genetic mechanisms. This is an example of the ability of this type of genomic 
analysis to identify pleiotropic effects, which is where a defect in a single gene can give rise to 
multiple, apparently unrelated phenotypes. Here we are extending the concept of pleiotropy 
beyond the single gene paradigm to encompass inherently complex traits driven by multiple 
genetic variants spread across the genome and that are typically outside of coding regions. LD 
score regression is not designed to identify the specific shared genetic variants responsible for 
both phenotypic traits, but instead focuses on establishing whether such pleiotropy exists between 
traits. 
Using Mendelian randomization, we found strong evidence that an alteration of lipid 
metabolism is causally linked to ALS. We undertook sensitivity analyses to reduce the 
possibility of bias in our results and replicated our findings across three different exposure 
GWASes, including a large, independent cohort obtained from the UK Biobank. 
Furthermore, we demonstrated that the increased risk of ALS due to coronary heart disease is 
driven by LDL cholesterol. Though hyperlipidemia only modestly increases the risk of ALS, 
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this effect likely operates over the lifetime of the individual, and the cumulative effect on 
disease risk may be substantial. 
Previous epidemiological studies have explored the role of blood lipids in the pathogenesis of 
ALS. These observational studies have yielded controversial results with many reporting that 
hyperlipidemia increases disease risk, and others suggesting the opposite 30-36. In addition to 
being underpowered, much of this previous research was based on blood lipid profiles 
obtained after diagnosis of ALS when ancillary factors may be influencing these levels 30-36.  
The singular advantage of Mendelian randomization is that it is agnostic to these confounders 
and can be considered nature’s randomized controlled trial. Based on genetic data that remain 
constant between the pre-symptomatic and symptomatic phases of the disease, it accurately 
pinpoints predisposing factors for the disease of interest. While this manuscript was under 
review, a link between blood lipids and the risk of ALS has been recently reported in 
European and East Asian populations using polygenic risk scores and Mendelian 
randomization 9, 10. These studies were performed involving a smaller cohort of ALS cases, 
and were based on the a priori hypothesis that blood lipids were involved in the pathogenesis 
of ALS. Our work extends these recent reports by definitely applying Mendelian 
randomization across a large number of phenotypic traits in an unbiased fashion, by 
replicating our findings in an independent cohort (UK Biobank), and by delineating the 
specific aspects of lipid metabolism relevant to the pathogenesis of ALS.  
Circulating blood cholesterol are multifunctional molecules, involved primarily in energy 
generation, as precursors or cofactors for signaling molecules, and in neuronal development 
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and function 37. Dysregulation of cholesterol homeostasis in the brain has been linked to 
many neurodegenerative diseases such as Huntington's disease, Parkinson's disease, 
Niemann-Pick disease type C, and, most notably, Alzheimer's disease 38. The generation and 
clearance of β-amyloid protein is regulated by cholesterol, and drugs that inhibit cholesterol 
synthesis lower this protein within neurons 39, as is the more recent finding that the two 
secretory forms (APPɑ  and APP β) of amyloid precursor protein (APP) have opposing 
associations with β-amyloid generation, cholesterol biosynthesis, and LDL receptor levels 40. 
The identification of the cholesterol transport protein apolipoprotein E as a major genetic 
risk factor for Alzheimer's disease is also consistent with a role for cholesterol in the 
pathogenesis of neurodegenerative disease 41-42. Despite this, the molecular mechanisms by 
which altered lipid metabolism leads to neuron degeneration are unclear. 
An important question arising from our analysis centers on why LDL may causally affect ALS, 
while at the same time LDL levels are not genetically correlated with ALS under the LD Score 
regression model. This apparent divergence is because the variants linked to these two traits are 
not pleiotropic, and again highlights the fact that Mendelian randomization and LD regression 
analysis investigate different aspects of the genetic architecture underlying diseases. Mendelian 
randomization allows us to compare two groups of people that differ by the genetic variants of 
interest and therefore by any modifiable factor to which those genetic variants relate. In this case, 
genetic variants that are associated with LDL metabolism affect LDL levels and a ratio measure is 
calculated to determine how much this estimated change in LDL level would predispose 
individuals to ALS. If substantial pleiotropy were present, we would find that the same genetic 
variants that affect LDL metabolism also increase the risk of ALS by themselves (i.e genetic 
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correlation). Such pleiotropy was not observed in our data. Instead, we found that the only 
mechanism by which ALS risk could be increased is through an increase of LDL cholesterol 
levels (i.e linear association). 
Our data lead us to propose that lowering blood cholesterol levels is a viable strategy for 
reducing risk associated with ALS. A similar approach may be effective in Alzheimer's 
disease where exposure to statins is associated with substantially reduced risk of dementia in 
observational studies 43-44. Though the American Heart Association guidelines for treating 
blood cholesterol to reduce cardiovascular risk are widely implemented in the community, 
they primarily focus on patients over the age of 50 45. An alternative strategy may be to 
identify a younger subpopulation at increased risk of developing ALS and to institute 
treatment with lipid-lowering agents. This approach would initially focus on individuals with 
a family history of ALS or frontotemporal dementia, and on pre-symptomatic cases carrying 
the C9orf72 repeat expansion; together these subtypes account for nearly one in five cases of 
ALS 46. Long-term monitoring would be required to detect side-effects from the medication, 
and to determine effect on the age of disease onset. 
We conclude by saying that the reported findings should be interpreted in the context of existing 
evidence from other research studies using different designs, and definite conclusions should not 
be elaborated uniquely based on Mendelian randomization results. Future randomized controlled 
trials should be considered as a proof of causality. 
 
Limitations to this study 
Our analyses were limited to only those GWAS studies present in two public databases, 
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namely LD-hub and MR Base. Furthermore, the available data are focused on European 
populations. We envisage that future studies may expand our findings by employing larger 
sample sizes, greater density across the genome, and importantly Non-European populations, 
highlighting the utility of an ALS resource that is constantly updated as new data become 
available.  
One of the main caveats of working with summary level data (rather than individual level 
data) is that there is no possibility to filter and exclude sample overlap. For Mendelian 
randomization analyses, we cannot exclude the possibility that samples from the same 
individuals were used in both the GWASes that we identified as significant exposures and in 
the ALS GWAS that we used as the outcome measure. Such sample overlap may bias 
estimates in MR and increase Type 1 error rates. We reviewed the origin of the European 
cohorts present in our ALS outcome and in the significantly associated exposures, and the 
results of this comparison are outlined in Table S11. Our data suggest that sample overlap had 
only a minimal effect on our results. We also performed sensitivity analyses by calculating 
the F-statistic parameter as described elsewhere 47. Our results showed that two of the three 
GWASes of interest for which F-statistic could be calculated were considered strong 
instruments and are unlikely to be susceptible to bias due to overlapping samples (F-statistic 
for LDL cholesterol = 59.02, F-statistic for coronary heart disease =742.2). Furthermore, 
sample overlap alone cannot account for our findings, as any sample overlap would be 
equally likely to occur across the diverse GWASes that we studied, and yet, we consistently 
identified altered lipid metabolism as a risk factor for ALS across multiple GWAS studies and 
across multiple populations. There is no realistic scenario in which sample overlap could have 
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been consistently confined to just GWASes involving lipid metabolism. However, since 
Mendelian randomization effect estimates are often small, mandating additional follow-up on 
connected pathways. 
A concern that might arise is to what extent hereditary cases of ALS carrying rare genetic 
variants might have influenced our analyses. One should expect that carrying large effect, 
rarer variants would not generally preclude the carrying of more common, small effect genetic 
risk factors which comprise the majority of GWAS results that were used for Mendelian 
randomization and LD Score regressions.  
Finally, we are aware that certain bias could exist due to undetectable issues in underlying 
GWAS results utilized in this survey, but the fact that we have replicated our results in 
independent GWASes alleviates this concern. 
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FIGURE LEGENDS 
Figure 1. Flowchart of analysis 
The ALS Research Resource is an interactive tool where the user can explore genetic 
correlations and causal associations across more than 700 traits. GWAS exposures used 
for LD score regressions are available in LD hub at http://ldsc.broadinstitute.org/ldhub/. 
GWAS exposures used for the Mendelian randomization analyses are available in MR 
Base at http://www.mrbase.org/; (A) The inclusion criteria used for LD score regression 
analyses comprise traits with heritability estimates within normal boundaries. (B) The 
inclusion criteria used for Mendelian randomization includes (i) GWAS with at least 
two associated SNPs with p-values less than 5.0x10-8, (ii) SNPs present in both the 
exposure and outcome (ALS) datasets or when not present their linkage-disequilibrium 
proxies (R2 value >= 0.8); and, (iii) independent SNPs (R2 < 0.001 with any other 
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associated SNP within 10 Mb), considered as the most stringent clumping threshold 
used when performing MR analyses. (C) LD score regression analyses included 751 
publicly available GWASes considered as exposures of interest versus the most recent 
ALS GWAS as an outcome, and (D) MR analyses were performed considering two 
phases. Phase I includes 345 available GWAS in the public domain as exposures of 
interest while phase II includes unpublished UK Biobank GWAS data. (E) Significantly 
associated GWASes with ALS at Inverse variance weighted (p < 0.05). (F) 
Significantly associated GWASes with ALS at Weighted median and MR Egger (p < 
0.05). (G) Causally linked GWASes with ALS after performing reverse causality, 
sensitivity and directionality analyses. (H) Multivariate analyses used to explore how 
each related exposure of interest independently contribute to ALS. GWAS, Genome-
Wide Association study; kb, kilobases; R2, clumping threshold; LDL, low-density 
lipoprotein. 
Figure 2. Bayesian colocalization plots 
A plot and B plot represent two independent LDL cholesterol-associated regions with 
posterior probability greater than 95 % of sharing a causal variant involved in ALS. 
Panels in column A show the region spanning chr5:73656720-75651786 where 
rs182826525 is likely the shared causal variant with a posterior probability of nearly 
100%. Panels in column B show the region spanning chr5:155390511-157388284 
where rs116226146 is likely the shared causal variant with a posterior probability of 
96%.  The first row displays the p-values from the LDL GWAS for each region. Color 
is coded by p-values in the ALS GWAS.  The second row displays the P-values from 
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the ALS GWAS for the same regions. Color is coded by P-values in the LDL GWAS.  
The third row shows local gene positions (with strands denoted by +/-), as well as 
recombination rates measured in cM/Mb. 38 The bottom row shows the posterior 
probabilities of a shared causal variant between LDL cholesterol and ALS. 
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Table 1. Linkage disequilibrium score regression results for traits genetically correlated 
with ALS 
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Trait Source rg [se] p-value FDRp-value h² [se]
Fluid intelligence score UKBB -0.338[0.067] 4.74E-07 1.78E-04
0.238
[0.011]
Qualifications: Other professional qualifications 
eg: nursing_ teaching UKBB
-0.257
[0.071] 3.00E-04 1.73E-02
0.047
[0.003]
Qualifications:
A levels/AS levels or equivalent UKBB
-0.255
[0.059] 1.61E-05 1.66E-03
0.097
[0.004]
Qualifications:
College or University degree UKBB
-0.249
[0.053] 2.77E-06 5.19E-04
0.168
[0.005]
Qualifications:
O levels/GCSEs or equivalent UKBB
-0.238
[0.069] 5.00E-04 2.68E-02
0.049
[0.003]
Age completed full time education UKBB -0.229[0.068] 7.00E-04 3.09E-02
0.084
[0.005]
Years of schooling 2016 27225129 -0.226[0.059] 1.00E-04 6.83E-03
0.127
[0.004]
Number of incorrect matches in round UKBB 0.229[0.06] 1.00E-04 6.83E-03
0.055
[0.003]
EDUCATION
Qualifications: None of the above UKBB 0.255[0.059] 1.49E-05 1.66E-03
0.098
[0.004]
Types of transport used
(excluding work): Walk UKBB
-0.403
[0.085] 2.11E-06 5.19E-04
0.033
[0.002]
Types of transport used (
excluding work): Public transport UKBB
-0.402
[0.092] 1.13E-05 1.66E-03
0.022
[0.002]
Types of physical activity
in last 4 weeks: Light DIY UKBB
-0.287
[0.07] 4.24E-05 3.54E-03
0.039
[0.002]
Types of physical activity
in last 4 weeks: Walking for pleasure UKBB
-0.286
[0.079] 3.00E-04 1.73E-02
0.037
[0.002]
Duration of moderate activity UKBB 0.283[0.084] 7.00E-04 3.09E-02
0.032
[0.002]
ACTIVITY
Job involves mainly walking or standing UKBB 0.216[0.065] 9.00E-04 3.56E-02
0.08
[0.004]
Exposure to tobacco smoke at home UKBB 0.42[0.122] 6.00E-04 3.00E-02
0.012
[0.002]
SMOKING Light smokers
(at least 100 smokes in lifetime) UKBB
0.427
[0.1] 1.77E-05 1.66E-03
0.077
[0.008]
OTHER
Frequency of tenseness /
restlessness in last 2 weeks UKBB
0.227
[0.068] 9.00E-04 3.56E-02
0.044
[0.003]
  
See supplementary materials for a description of the phenotypes included in the UK Biobank dataset, and 
Figure 1 for the number of traits screened as part of the LD score regression analysis. Source: number 
denotes PubMed identification numbers; UKBB, UK Biobank; rg, regression; se, standard error; FDR, 
false discovery rate adjusted p-value; h², observed narrow-sense heritability. 
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Table 2. Mendelian randomization results for exposures causally linked to ALS 
 
 
id,specific code attributed to each trait by MR Base; No.of SNPs, number of SNPs;  
OR, Odds ratio; CI, confidence interval; LDL, low densitity lipoprotein. 
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Inverse variance 
weighted             MR Egger     Weighted  Median
Exposure  Source No. of SNPs
OR
[CI 95 %] p-value
OR
[CI 95 %] p-value
OR
[CI 95 %] p-value
LDL cholesterol 
id:300 24097068 78
1.116
[1.03-1.20] 0·003
1.115 
[1.00-1.23] 0·054
1.108
[1.00-1.226] 0·046
Coronary heart 
disease id:7 26343387 37
1.063
[1.0-1.13] 0·047
1.175 
[1.01-1.35] 0·032
1.116
[1.020-1.220] 0·015
Self-reported: 
high cholesterol 
id:UKB-a:108
UKBB 49 2.389[1.48-3.84] 0·0003
2.669 
[1.08-6.55] 0·038
2.110
[1.021-4.357] 0·044
Table 3. Multivariable analysis to estimate the simultaneous effects of two exposures 
 
a) Analysis comparing LDL cholesterol versus self-reported cholesterol 
 
Exposure No. of SNPs beta se p-value 
LDL cholesterol || id:300 72 0·175 0·084 0·019 
Self-reported high cholesterol || id:UKB-a:108 34 -0·847 0·722 0·120 
 
b) Analysis comparing LDL cholesterol versus coronary heart disease 
 
Exposure No. of SNPs beta se p-value 
LDL cholesterol || id:300 74 0·087 0·040 0·014 
Coronary heart disease || id:7 26 0·027 0·038 0·239 
 
id, specific code attributed to each trait by MR Base; se, standard error; No. of SNPs, number 
of SNPs; LDL: low density lipoprotein. 
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